NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
03 November 2025
| Name: | INVEX THERAPEUTICS LTD (IXC) |
| ISIN: | AU0000048621 |
| Date of Listing: | 05 July 2019 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 632 145 334ABN: 29 632 145 334
Registration Date: 08 March 2019
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Automic Group
Level 5, 126 Philip Street Sydney NSW 2000
GPO Box 5193 Sydney NSW 2001
Tel : 1300 288 664 or +61 2 9698 5414
Fax : +61 2 8583 3040
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Invex Therapeutics Ltd will be lifted immediately following the release by IXC of an announcement regarding a material acquisition and the Company responding to a price query from ASX. | 30/09/2025 |
The company releases a response to an ASX price and volume query. | 30/09/2025 |
The company has discontinued exclusive negotiations with a therapeutic development company focused on a rare neurological disease due to instability from a requisition notice to remove 2 out of 3 Directors. The Board aims to continue its strategy of diversifying its portfolio by seeking complementary neurological treatment assets despite challenges in the current volatile environment. Following the completion of the Phase 3 IIH EVOLVE clinical trial, the Board has been reviewing various opportunities, but many were deemed unsuitable. In June 2025, a promising investment opportunity was identified in a complementary neurological treatment asset. | 30/09/2025 |
The company will hold its Annual General Meeting on 25 November 2025, with the closing date for director nominations being 7 October 2025. Shareholders will be informed in October 2025. | 29/09/2025 |
The company requests an extension to its voluntary suspension of securities trading, pending an announcement and response to ASX price query. The suspension remains in place until 30 September 2025. | 29/09/2025 |
The securities of Invex Therapeutics Limited will be suspended from quoting under Listing Rule 17.2 at IXC's request, pending an announcement. The suspension will continue until either the end of the requested voluntary suspension period or the announcement's release to the market. IXC's request is attached for market information. | 25/09/2025 |
listed entity carried for record purposes only | 05/07/2019 |
The suspension of trading in the securities of Invex Therapeutics Ltd will be lifted immediately following the release by IXC of an announcement regarding a material acquisition and the Company responding to a price query from ASX. | 30/09/2025 |
The company releases a response to an ASX price and volume query. | 30/09/2025 |
The company has discontinued exclusive negotiations with a therapeutic development company focused on a rare neurological disease due to instability from a requisition notice to remove 2 out of 3 Directors. The Board aims to continue its strategy of diversifying its portfolio by seeking complementary neurological treatment assets despite challenges in the current volatile environment. Following the completion of the Phase 3 IIH EVOLVE clinical trial, the Board has been reviewing various opportunities, but many were deemed unsuitable. In June 2025, a promising investment opportunity was identified in a complementary neurological treatment asset. | 30/09/2025 |
The company will hold its Annual General Meeting on 25 November 2025, with the closing date for director nominations being 7 October 2025. Shareholders will be informed in October 2025. | 29/09/2025 |
The company requests an extension to its voluntary suspension of securities trading, pending an announcement and response to ASX price query. The suspension remains in place until 30 September 2025. | 29/09/2025 |
The securities of Invex Therapeutics Limited will be suspended from quoting under Listing Rule 17.2 at IXC's request, pending an announcement. The suspension will continue until either the end of the requested voluntary suspension period or the announcement's release to the market. IXC's request is attached for market information. | 25/09/2025 |
listed entity carried for record purposes only | 05/07/2019 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 24/08/2023 | Thomas Duthy | 178,738 | $0.180 | $32,173 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Narelle Warren | CFO, Company Secretary | 05/07/2019 |
| David Wheeler | Non Exec Director | 08/11/2023 |
| Thomas Duthy | Executive Director | 01/10/2020 |
| David McAuliffe | Interim Chairman | 05/07/2019 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Megan Baldwin | Independent Director | 16/02/2021 | 30/06/2024 |
| Jason Loveridge | Non Exec Chairman | 05/07/2019 | 10/07/2023 |
| Alexandra Sinclair | Executive Director | 05/07/2019 | 10/07/2023 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
